$IMMU - On our trading list. Dropped due to a drug delay concern. Under $10 or less this is a still a good bet. Today Goldman Sachs analyst gives their opinion. Cowen gave a good analysis 2 days ago, check here for that article. Cowen's comments/analysisAnalysts so far have had different opinions. Goldman is negative while Cowen was still positive.Immunomedics downgraded to Sell from Buy at Goldman SachsGoldman Sachs analyst Paul Choi double downgraded Immunomedics to Sell from Buy with a price target of $5, down from $24. The stock closed Thursday up 51c to $10.65. A Form 483 was published detailing ten observations of quality control, procedural, maintenance and other issues observed during the FDA's most recent inspection of the company's Morris Plains, NJ facility, Choi tells investors in a research note. Based on this, the analyst now thinks it is unlikely that Immunomedics' sacituzumab govitecan will be approved at its June 2, 2020 FDA action date for triple negative breast cancer. Choi finds it unclear whether Immunomedics will be able to address these concerns adequately, and is cautious on the company's ability to execute on the other ongoing clinical studies without the revenue generated in triple negative breast cancer. $IMMU, Immunomedics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page